Oncolytics Biotech Inc.

Good afternoon and welcome to Oncolytics Biotech's second quarter 2024 conference call. All participants are now in a listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Jan Patton, Director of Investor Relations and Communication.

Please go ahead. Thank you, Operator.

Earlier today, OnClinics issued a press release providing recent operational highlights and financial results for the second quarter of 2024. A replay of today's call will be available on the event section of the OnClinics website. And after remarks from company management, we will open the call for Q&A. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of Pella Reader App. including statements regarding the company's mission, strategy, and milestones, the company's belief as to the potential and mechanism of action of Pell Rear Up as a cancer therapeutic, our belief that we are positioned to execute on our key priorities and reach multiple milestones throughout the second half of the year and into 2025, our potential registrational opportunities for Pell Rear Up, anticipated timing of the release of additional data, our cash runway, and other statements related to anticipated developments in the company's business. These statements are based on management's current expectations and beliefs and are subject to a number of factors which involve known and unknown risks, delays, uncertainties, and other factors not under the company's control that may cause actual results, performance, or achievements of the company to be materially different from the results, performance, or expectations implied by these forward-looking statements. In any forward-looking statement in which Oncleric expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith, and our belief to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, actions of regulatory agencies, and those other factors detailed in the company's filings with CDAR and the SEC. OnClinic does not undertake any obligation to update these forward-looking statements except as required by applicable laws. Joining me to discuss the substantial progress made during the second quarter are a few members of the management team, including Chair of Oncologics Board of Directors and Interim CEO, Wayne Pisano, Chief Medical Officer, Dr. Tom Heinemann, Chief Financial Officer, Kirk Look, Vice President, Business Development, Christophe Degois. And with that, it's my pleasure to turn the call over to Wayne. Wayne?